Research is being conducted on the relationship between metabolic reprogramming and immune regulation in acute myeloid leukemia. Studies are exploring the molecular mechanisms and therapeutic implications of targeting the metabolic and immune axes in cancer. The findings suggest that metabolic reprogramming plays a role in leukemia progression and that targeting specific metabolic pathways may have therapeutic potential.